Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults (1993)
    Springer
    Supportive care in cancer 1 (1993), S. 139-144 
    Details
    ISSN: 1433-7339
    Keywords: Acyclovir ; Bacteraemia ; Leukaemia induction treatment
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We prospectively tested the hypothesis that prevention of herpes simplex virus infection with acyclovir might also reduce the incidence of bacterial infections in adult patients with acute leukaemia. During the first induction therapy a double-blind, randomized and placebo-controlled study was undertaken. Fifty-two patients were treated with 200 mg acyclovir orally four times daily throughout the induction period, whereas 55 patients received placebo. The groups were comparable with regard to age, cytotoxic chemotherapy and duration of neutropenia. Bacteraemias were significantly fewer in the acyclovir group (20 versus 41 episodes; P=0.007). The number of isolated microorganisms causing bacterial or fungal infections was also lower during acyclovir prophylaxis (52 isolates, versus 93 isolates; P=0.02). There was no significant differenc between the groups with regard to the number of clinically documented infections or fevers of unknown origin. Herpes simplex virus isolations occurred only in the placebo group (P=0.001). Thus, oral acyclovir prophylaxis was associated with reductions of all microbiologically documented infections suggesting that prevention of herpes simplex virus reactivation in acute leukaemia patients may reduce the occurrence of other infections.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00366060
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease (2000)
    Springer
    Annals of oncology 11 (2000), S. 1405-1411 
    Details
    ISSN: 1569-8041
    Keywords: Hodgkin's disease ; interleukin-10 ; prognosis ; prognostic score ; sCD30
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:The International Prognostic Score (IPS) identifiesseven independent factors predicting progression-free and overall survival inadvanced stage Hodgkin's disease (HD). The IPS is also applicable in limiteddisease. However, the IPS does not identify patients with a very poorprognosis. The aim of this study was to define biological markers which mayadd to the IPS in predicting outcome. Patients and methods: One hundred forty-five patients (〉15years) with HD of all stages and histopathology subgroups were included. Inaddition to factors included in the IPS, serum levels of CRP, sCD4, sCD8,sCD25, sCD30, sCD54, interleukin (IL)-10, β2-microglobulin and thymidinekinase were analysed. Results:The strongest predictors of a poor cause-specificsurvival (CSS) in univariate analyses were: increased serum levels of IL-10,sCD30 and CRP, anaemia, low levels of albumin (P〈 0.001); stageIV (P= 0.003), age ≥45 years (P= 0.006), increasedserum levels of sCD25 (P= 0.010), low lymphocyte counts (P= 0.020). Serum IL-10 added prognostic information to that achieved bythe IPS: patients with a high score and increased serum IL-10 had a very pooroutcome with a five-year CSS of 38%. Patients with increased serumlevels of sCD30 and a high score also had a poor outcome with a five-year CSSof 54%. Conclusion:Serum levels of IL-10 and sCD30 may add to IPS inprediction of outcome in HD, and should be validated in large, prospectivestudies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1026551727795
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphoma (1998)
    Springer
    Annals of oncology 9 (1998), S. 1213-1217 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; CHOP ; etoposide ; high-grade non-Hodgkin's lymphoma ; risk factors
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Second- and third-generation chemotherapy protocols for the treatment of aggressive non-Hodgkin's lymphomas (NHL) have considerable, and age-related, toxic effects. In addition, they do not seem to prolong overall survival in comparison to standard CHOP chemotherapy. In this phase II study we investigated the feasibility and efficacy of the addition of etoposide to the conventional CHOP regimen. Patients and methods: Toxicity and clinical efficacy were determined in 132 patients with previously untreated high-grade NHL. There were 51 patients in clinical stage I and II and 81 patients in stage III and IV, with a median age of 54 years (range 17–85). Patients received standard-dose CHOP plus etoposide 100 mg/m2 i.v. on day 1 and 200 mg/m2 p.o. on days 2–3. Results: The overall response rate was 84%, with 70% complete and 14% partial responses. The predicted three- and five-year survivals for the group as a whole were 60% and 53%, respectively, and the corresponding disease-free survivals for patients achieving complete remissions were 65% and 56%, respectively. Outcome was not different from that of CHOP-treated patients in a recently completed Nordic study performed during the same time period. Myelosuppression (WHO grade 3–4), observed in 87% of patients and infectious complications (WHO grade 3–4) in 33%, dominated the toxicity profile of this regimen. Fifty-seven of 92 complete responders (62%) received 6–8 CHOP-E cycles with no reductions in planned dose intensity. LDH level higher than normal, extranodal sites = 2, stage III–IV at diagnosis were all indicators of a poor survival. Conclusions: We conclude that CHOP-E treatment is effective in high-grade NHL. However, mainly due to severe myelosuppression frequent schedule modifications were required and the results are not obviously superior to those of conventional CHOP.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008446430765
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...